Polymerase News and Research

RSS

Emergence of a new SARS-CoV-2 variant from Southern France

A new study has described the emergence of another new SARS-CoV-2 variant from south-eastern France with Cameroonian origin.

6 Jan 2022

Host kinase identified as an inhibition target for SARS-CoV-2

In this experiment, the chemical probe SGC-CK2-1 inhibited virus replication at nanomolar concentration, showing a highly selective effect on the kinase.

6 Jan 2022

SARS-CoV-2 appears to persist in organs throughout the body for months

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leads to asymptomatic or mild symptoms in most cases. However, in a significant minority, it causes moderate or severe disease, with lung damage and sometimes multi-organ dysfunction, the origin of which is currently a matter of intense debate.

6 Jan 2022

Scientists estimate transmission advantage of Omicron over Delta variant as +105%

Researchers use statistical models to assess the transmission of the SARS-CoV-2 Omicron using variant-specific screening tests and genome sequencing.

5 Jan 2022

Comparison of the mutational profile of Omicron with other SARS-CoV-2 lineages

Researchers from nference labs in Massachusetts have been examining the origins of a particular mutation in the Omicron variant.

5 Jan 2022

Israeli study confirms drop in BNT162b2 efficacy after six months

Researchers determine whether BNT162b2 vaccination has become less efficient in preventing infection over time.

4 Jan 2022

Study suggests increased vaccine breakthrough for SARS-CoV-2 Omicron variant in Houston, Texas

A recent study reveals early signals of substantially increased vaccine breakthrough for the Omicron variant of SARS-CoV-2 in Houston, Texas.

4 Jan 2022

Characteristics and outcomes in patients hospitalized with COVID-19 in South Africa

A new research letter assessed patients hospitalized with a positive SARS-CoV-2 test during the fourth wave compared to the previous waves.

4 Jan 2022

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

An independent study confirms that current and prospective antiviral treatments are effective in inhibiting severe infection from SARS-CoV-2.

4 Jan 2022

Very high rates of asymptomatic infection with Omicron compared to prior SARS-CoV-2 variants

The advent of the B.1.1.529 (Omicron) severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) variant, detected initially in Botswana and South Africa and now found in over 135 countries as of January 3, 2022, has sparked fears of a new global wave of infections and hospitalizations

3 Jan 2022

Modeling shows SARS-CoV-2 Omicron will place a severe burden on UK's health services

Researchers use data and a mathematical model to determine the impact of the SARS-CoV-2 Omicron variant on future risk of infection.

3 Jan 2022

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Researchers analyzed convalescent sera and sera from immunized individuals to demonstrate the evasion of antibodies by the SARS-CoV-2 Omicron variant.

3 Jan 2022

Omicron surges in England especially in young

Researchers used data from the REACT-1 study to analyze SARS-CoV-2 community prevalence and the emergence of the Omicron variant in England.

3 Jan 2022

Less severe clinical consequences of infection with SARS-CoV-2 Omicron variant

New evidence implies that the Omicron variant may cause a less severe and/or faster recovery from clinical COVID-19 disease.

31 Dec 2021

SARS-CoV-2 omicron variant may be less severe than the delta variant

A new study reveals that omicron infections in South Africa are associated with lower rates of hospital admissions and lower disease severity compared to beta and delta infections.

31 Dec 2021

Antibody neutralization of SARS-CoV-2 Omicron variant via BNT162b2 vaccine booster dose

New study findings highlight the need for a rapid booster vaccine campaign to prevent COVID-19 caused by the Omicron variant since the neutralization of Omicron by the two-dose BNT162b2 vaccine is not effective in controlling the spread of the infection.

30 Dec 2021

Polymerase News and Research

Emergence of a new SARS-CoV-2 variant from Southern France

Host kinase identified as an inhibition target for SARS-CoV-2

SARS-CoV-2 appears to persist in organs throughout the body for months

Scientists estimate transmission advantage of Omicron over Delta variant as +105%

Comparison of the mutational profile of Omicron with other SARS-CoV-2 lineages

Israeli study confirms drop in BNT162b2 efficacy after six months

Study suggests increased vaccine breakthrough for SARS-CoV-2 Omicron variant in Houston, Texas

Characteristics and outcomes in patients hospitalized with COVID-19 in South Africa

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

Very high rates of asymptomatic infection with Omicron compared to prior SARS-CoV-2 variants

Modeling shows SARS-CoV-2 Omicron will place a severe burden on UK's health services

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Omicron surges in England especially in young

Less severe clinical consequences of infection with SARS-CoV-2 Omicron variant

SARS-CoV-2 omicron variant may be less severe than the delta variant

Antibody neutralization of SARS-CoV-2 Omicron variant via BNT162b2 vaccine booster dose

P323L mutations in SARS-CoV-2 are highly predictive of the emergence of new variants

Rapid antigen tests show lower sensitivity for Omicron than for earlier SARS-CoV-2 variants

Omicron analysis shows no clear evidence for increased virulence or lethality

MRNA boosters shown to increase protection against SARS-CoV-2 Omicron

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News